Mar 14, 2017 11:30 am UTC| Business
Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure Protocol’s best practice infiltration technique for the use of EXPAREL will...
Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results
Mar 14, 2017 11:30 am UTC| Business
ALPHARETTA, Ga., March 14, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial...
Mar 14, 2017 11:30 am UTC| Business
Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) inMenkes disease, a rare and fatal pediatric disease Cyprium licenses preclinical AAV-ATP7A gene...
Albireo Reports 2016 Financial Results
Mar 14, 2017 11:30 am UTC| Business
Promising Phase 2 data for A4250 in pediatric cholestatic liver disease Initiation of A4250 Phase 3 trial planned for 2H 2017 JNDA filing for elobixibat by licensee EA Pharma Consummation of business combination to...
Mar 14, 2017 11:30 am UTC| Business
DUBLIN, Ireland and TREVOSE, Pa., March 14, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
Mar 14, 2017 11:15 am UTC| Business
First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary lipid nanoparticle...
Euronet Worldwide Proposes to Acquire MoneyGram for $15.20 Per Share
Mar 14, 2017 11:05 am UTC| Business
Offer Represents an Approximately 15% Premium Over MoneyGram’s Existing Agreement with Ant Financial and a Premium Of Approximately 28% to the Company’s Closing Price on the Day Prior to the Ant Financial Transaction...